Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells

Molecular and Cellular Endocrinology

Volumn 249, Issue 1-2, 2006, Pages 116-122

  Collado, Beatriz ^a   Sánchez Chapado, Manuel ^a,b   Prieto, Juan C ^a   Carmena, María J ^a  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Angiogenesis; HIF; Hypoxia; Prostate cancer; VEGF; VIP receptors

Indexed keywords

FIH 1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; NICKEL; PROTEIN INHIBITOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CELL NUCLEUS MEMBRANE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIC CELL; MALE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION; TRANSACTIVATION;

CELL HYPOXIA; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; NICKEL; PROSTATIC NEOPLASMS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; REPRESSOR PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASOACTIVE INTESTINAL PEPTIDE;

EID: 33645848158     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2006.02.004     Document Type: Article

References (40)

1. Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet. 5 (2004) 27-38
2. Chang J.T., Chen I.H., Liao C.T., Wang H.M., Hsu Y.M., Hung K.F., Lin C.J., Hsieh L.L., and Cheng A.J. A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin. Biochem. 35 (2002) 591-596
3. Choi K.S., Bae M.K., Jeong J.W., Moon H.E., and Kim K.W. Hypoxia-induced angiogenesis during carcinogenesis. J. Biol. Chem. Mol. Biol. 36 (2003) 120-127
4. Collado B., Carmena M.J., Sánchez-Chapado M., Ruíz-Villaespesa A., Bajo A.M., Fernández-Martínez A.B., Varga J.L., Schally A.V., and Prieto J.C. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int. J. Oncol. 26 (2005) 1629-1635
5. Collado B., Gutiérrez-Cañas I., Rodríguez-Henche N., Prieto J.C., and Carmena M.J. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul. Pept. 119 (2004) 69-75
6. 2+ signalling. Implications in angiogenesis and neuroendocrine differentiation. Biochim. Biophys. Acta 1744 (2005) 224-233
7. Cross M.J., and Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22 (2001) 2001-2007
8. Datta K., Li J., Bhattacharya R., Gasparian L., Wang E., and Mukhopadhyay D. Protein kinase Cζ transactivates hypoxia-inducible factor α by promoting its association with p300 in renal cancer. Cancer Res. 64 (2004) 456-462
9. Dragon S., Offenhauser N., and Baumann R. cAMP and in vivo hypoxia induce tob, ifr1, and fos expression in erythroid cells of the chick embryo. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282 (2002) 1219-1226
10. Fahrenkrug J., and Said S.I. VIP, PACAP, glucagons, and related peptides. Ann. NY. Acad. Sci. 921 (2000) 1-110
11. Fukuchi M., Sakuragawa S., Tabuchi A., and Tsuda M. Calcium signal-mediated expression of the vasoactive intestinal polypeptide gene and its small contribution to activity-dependent survival of mouse cerebellar granule cells. J. Neurosci. Res. 77 (2004) 26-34
12. García-Fernández M.O., Solano R.M., Carmena M.J., Busto R., Bodega G., Ruíz-Villaespesa A., and Sánchez-Chapado M. Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue. Peptides 24 (2003) 893-902
13. Graven K.K., McDonald R.J., and Farber H.W. Hypoxic regulation of endothelial glyceraldehide-3-phosphate dehydrogenase. Am. J. Physiol. 274 (1998) C347-C355
14. Gutiérrez-Cañas I., Juarranz M.G., Collado B., Rodríguez-Henche N., Chiloeches A., Prieto J.C., and Carmena M.J. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. Prostate 63 (2005) 44-55
15. Hahm S.H., and Eiden L.E. Cis-regulatory elements controlling basal and inducible VIP gene transcription. Ann. NY. Acad. Sci. 865 (1998) 10-26
16. Huang L.E., and Bunn H.F. Hypoxia-inducible factor and its biomedical relevance. J. Biol. Chem. 278 (2003) 19575-19578
17. Huang L.E., Ho V., Arany Z., Krainc C., Galson D., Tendler D., Livingstone D.M., and Bunn H.F. Erythropoietin gene regulation depends on heme-depending oxygen sensing and assembly of interacting transcription factors. Kidney Int. 51 (1997) 548-553
18. Jackson M.W., Roberts J.S., Heckford S.E., Ricciardelli C., Stahl J., Horsfall D.J., and Tilley W.D. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 62 (2002) 854-859
19. Juarranz M.G., Bolaños O., Gutiérrez.Cañas I., Lerner E.A., Robberecht P., Carmena M.J., Prieto J.C., and Rodríguez-Henche N. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell Signal. 13 (2001) 887-894
20. Karacay B., O'Dorisio M.S., Summers M., Robinson M., and Bonthius D.J. VIP receptor 1 (VPAC1) promoter targets the expression of a reporter gene to cerebellum and adrenal medulla in transgenic mice. Regul. Pept. 116 (2003) 1-12
21. Kusakabe T., Hirokawa H., Oikawa S., Matsuda H., Kawakami T., Takenaka T., and Hayashida Y. Morphological changes in the rat carotid body 1, 2, 4 and 8 weeks after the termination of chronically hypocapnic hypoxia. Histol. Histopathol. 19 (2004) 1133-1140
22. Laburthe M., and Couvineau A. Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regul. Pept. 108 (2002) 165-173
23. Lando D., Peet D.J., Whelan D.A., Gorman J.J., and Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 295 (2002) 858-861
24. Liekens S., De Clerck E., and Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61 (2001) 253-270
25. Liu D., Krajniak K., Chun D., Sena M., Casillas R., Lelievre V., Nguyen T., Bravo D., Colburn S., and Waschek J.A. VIP gene transcription is regulated by far upstream enhancer and repressor elements. Biochem. Biophys. Res. Commun. 284 (2001) 211-218
26. Mabjesh N.J., Willard M.T., Frederickson C.E., Zhong H., and Simons J.W. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop pf tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin. Cancer Res. 9 (2003) 2416-2425
27. Mukkopadhyay D., and Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin. Cancer Biol. 14 (2004) 123-130
28. Namiki A., Brogi E., Kearney M., Kim E.A., Wu T., Coffinhal T., Varticovski L., and Isner J.M. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J. Biol. Chem. 270 (1995) 31189-31195
29. Peyronnet J., Poncet L., Denoroy L., Pequignot J.M., Lagercrantz H., and Dalmaz Y. Plasticity in the phenotypic expression of catecholamines and vasoactive intestinal peptide in adult rat superior cervical and stellate ganglia after long-term hypoxia in vivo. Neuroscience 91 (1999) 1183-1194
30. Powis G., and Kirkpatrick L. Hypoxia inducible factor-1 alpha as a cancer drug target. Mol. Cancer Ther. 3 (2004) 647-654
31. Prandota J. Possible pathomechanisms of sudden infant death syndrome: key role of chronic hypoxia, infection/inflammation states, cytokine irregularities, and metabolic trauma in genetically predisposed infants. Am. J. Therap. 11 (2004) 517-546
32. Quintero M., Mackenzie N., and Brennan P.A. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur. J. Surg. Oncol. 30 (2004) 465-468
33. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8 (2002) 62-67
34. Semenza G.L. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 64 (2002) 993-998
35. Sreedharan S.P., Huang J.X., Cheung M.C., and Goetzl E.J. Structure, expression, and chromosomal localization of the type I vasoactive intestinal peptide receptor gene. Proc. Natl. Acad. Sci. USA 92 (1995) 2939-2943
36. Steiner H., Berger A.P., Godoy-Tundidor S., Bjartell A., Lilja H., Bartsch G., Hobisch A., and Culig Z. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur. J. Cancer 40 (2004) 1066-1072
37. Symes A., Gearan T., Eby J., and Finks J.S. Integration of Jak-Stat and AP-1 signaling pathways at the vasoactive intestinal peptide cytokine response element regulates ciliary neurotrophic factor-dependent transcription. J. Biol. Chem. 272 (1997) 9648-9654
38. Veikkola T., and Alitalo K. VEGFs receptors and angiogenesis. Semin. Cancer Biol. 9 (1999) 211-220
39. Whyatt D.J., De Boer E., and Grosveld F. The two zinc finger-like domains of GATA-1 have different DNA binding specificities. EMBO J. 12 (1993) 4993-5005
40. Xie K., Wei D., Shi Q., and Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 15 (2004) 297-324